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Abstract. Background/Aim: The identification of novel
prognostic biomarkers for melanoma metastasis is essential
to improve patient outcomes. To this aim, we characterized
miRNA expression profiles in relation to metastasis in
melanoma and correlated miRNAs expression with clinical-
pathological factors. Materials and Methods: MiR-145-5p,
miR-150-5p, miR-182-5p, miR-203-3p, miR-205-5p and miR-
211-5p expression levels were analyzed in primary cutaneous
melanomas, including thin and thick melanomas, and in
melanoma metastases by quantitative Real-Time PCR.
Results: A significantly lower miR-205-5p expression was
found in metastases compared to primary melanomas.
Furthermore, a progressive down-regulation of miR-205-5p
expression was observed from loco-regional to distant
metastasis. Significantly lower miR-145-5p and miR-203-3p
expression levels were found in cases with Breslow thickness
>1 mm, high Clark level, ulceration and mitotic rate
≥1/mm2. Conclusion: Our findings point to miR-205-5p as
potential biomarker of distant metastases and to miR-145-5p
and miR-203-3p as markers of aggressiveness in melanoma. 
Cutaneous melanoma is increasing in incidence worldwide (1).
In Italy, the incidence of cutaneous melanoma is about 5-7
cases/100,000 per year (2). From a clinical and biological
standpoint, melanoma is a heterogeneous and unpredictable
disease. In early detected melanoma, surgical excision remains
the best choice of treatment and is curative in the vast majority
of cases (3). However, when diagnosed at an advanced stage
melanoma is metastatic (4) and, despite the scientific and
technological advancements in the oncology field, there are
currently no treatments capable of permanently treating
patients with metastatic melanoma. For this reason, the most
important strategy to reduce mortality is the early detection of
the primary tumor and the identification of patients at high-
risk of metastatic dissemination (5). 
Main prognostic factors in primary melanomas include
Breslow thickness, presence of ulceration, lymph node
involvement and distant metastases (6). Breslow thickness
provides the most useful histological information for
prognosis in cutaneous melanoma. 
Thin melanomas, which are lesions ≤1.00 mm in Breslow
thickness, have an excellent prognosis (7). However, about
5-10% of patients with thin melanoma develop metastases,
fatal in 5% of the cases (7-9). Therefore, there is still
controversy over the best way to use the clinical-pathological
features to predict melanoma progression and metastasis
development, and further molecular biomarkers are needed
to identify cases with a high-risk of metastasis (10).
An increasing number of studies have shown that
microRNAs (miRNAs), small (22 nucleotides) single-stranded
non-coding RNAs that negatively regulate the expression of
more than 60% of human genes (11), play an important role
in different biological processes, including cell survival,
apoptosis, cell cycle regulation and differentiation (12).
MiRNA misregulation and the subsequent alteration of target
gene expression may contribute to the development and
progression of different types of cancer, including melanoma
(11, 13). Several studies have underlined the high potential of
miRNAs as diagnostic, prognostic and therapeutic markers in
melanoma (14-16).
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To date, the majority of studies analyzing miRNA
expression in melanoma have focused on the comparison
between tumor and normal tissue, or between primary
melanoma and metastases (5, 11, 17-19). To our knowledge,
the potential role of miRNAs as prognostic biomarkers of
metastases in primary thin melanomas has not yet been
evaluated.
In the present study, the expression profile of six miRNAs
(miR-145, miR-150, miR-182, miR-203, miR-205, miR-211)
involved in invasion and metastasis of melanoma (5, 11, 19-
22), were analyzed in primary cutaneous melanomas,
including thin and thick melanomas, and in melanoma
metastases in order to: identify possible differences in
miRNA expression profile related to metastasis and
distinguish patients at risk of metastases; correlate miRNAs
expression with clinical-pathological factors.
Materials and Methods
Sample information. A series of 32 primary cutaneous melanoma
cases, including 16 thin (Breslow thickness ≤1.00 mm) and 16 thick
(Breslow thickness >1.00 mm) melanomas, was analyzed in this
study. Eight samples of metastatic specimens (four cutaneous, three
lymph node and one lung metastases) were also analyzed. For three
cases, matched primary tumor and metastatic specimens were
available.
The series analyzed was retrospectively collected between April
2009 and April 2017 at the Department of Internal Medicine and
Medical Specialties and Department of Radiology Oncology, and
Anatomo-Pathology of Sapienza University of Rome and the
Laboratory of Dermatopathology and Dermato-oncology and
Preventive Unit of San Gallicano Institute of Rome.
All primary melanomas were characterized for the main clinical-
pathological features, including age at diagnosis, sex, Breslow
thickness, Clark level, presence of ulceration, tumor-infiltrating
lymphocyte (TIL) grade based on assessment of absent, mild,
moderate, or marked density (TIL grade 0-III) and mitotic rate
(number of mitoses/mm2) (23, 24). Clinical follow-up ranged from
24 to 124 months (mean 63, median 48 months). For each study
participant, sections of formalin-fixed paraffin-embedded (FFPE)
tumor samples together with informed consent with a detailed
description of the study protocol were obtained.
The study was approved by the Local Ethical Committee
(Sapienza University of Rome, Prot. 873/13) and performed
according to the Helsinki’s declaration.
RNA extraction and miRNA expression analysis. For each sample,
total RNA was extracted from 5-10 μm FFPE tumor sections, using
miRNeasy FFPE kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Microdissection was applied to all
samples to enrich in tumor cells. RNA quantity and quality were
assessed using Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA). 
The expression profile of mature miRNAs for miR-145-5p, miR-
150-5p, miR-182-5p, miR-203-3p, miR-205-5p and miR-211-5p
was investigated in primary melanoma samples and metastatic
specimens by quantitative Real-Time PCR (qRT-PCR) using
TaqMan Advanced miRNA Assays (Applied Biosystem, Carlsbad,
CΑ, USA). MiR-92a-3p, miR-103a-3p, miR-191-5p were used as
endogenous controls for the normalization of miRNAs expression. 
Reverse transcription was performed using TaqMan Advanced
miRNA cDNA Synthesis Kit (Applied Biosystem) following
manufacturer’s protocol, and qRT-PCR was carried out on a 7500
Fast Real-Time PCR platform (Applied Biosystem). This method
allows to quantify mature miRNAs with high sensitivity and
specificity starting from 10 ng of total RNA input.
Commercially available TaqMan assays for target and control
miRNAs were used (Life Technologies). Each sample was run in
triplicate and relative miRNA expression levels were determined by the
ΔCt method (where ΔCt=Cttarget gene – Ctmean of the endogenous controls) and
expressed as 2–ΔCt. Appropriate negative controls were also included
in each experiment.
Statistical analysis. Unsupervised hierarchical clustering analysis
was performed to evaluate relevant clusters and co-expression.
Dendrograms and heatmap were generated using Euclidean distance
matrix and complete linkage. 
The non-parametric Mann-Whitney-Wilcoxon test was used to
compare relative miRNA expression levels for each miRNA in
primary non-metastatic melanomas, primary metastatic melanomas
and metastatic specimens. 
Associations between miRNA expression levels and clinical-
pathological characteristics were evaluated using linear regression
analysis, and the non-parametric Mann-Whitney-Wilcoxon or
Kruskal-Wallis test, where appropriate. A p-value ≤0.05 was
considered statistically significant. All statistical analyses were
performed with the R software (www.r-project.org).
Results 
MiRNA expression analysis in primary melanomas and
melanoma metastases. A series of 32 primary cutaneous
melanoma cases, comprising 16 thin and 16 thick melanomas
and including 17 non-metastatic and 15 metastatic cases, was
analyzed (Figure 1). Eight samples of metastatic specimens,
including three samples with matched primary tumor, were
also examined. 
As shown in Table I, the mean age at melanoma diagnosis
was 59.3 years (range=18-92 years) and a comparable
number of male and female individuals (53.1% and 46.9%,
respectively) were included in the study. In the vast majority
melanoma cases showed Clark level III (46.9%), absence of
ulceration (81.2%) and TIL grade I-II (71.9%). A mitotic rate
<1/mm2 and ≥1/mm2 was detected in 53.1% and 46.9% of
cases, respectively.
Overall, expression levels of miR-145-5p, miR-150-5p,
miR-182-5p, miR-203-3p, miR-205-5p and miR-211-5p were
examined in 40 samples (32 primary melanomas and eight
metastases). 
Unsupervised hierarchical clustering analysis identified
two principal groups of clustered miRNAs: one group
including miR-211-5p, miR-150-5p and miR-145-5p, and the
other group including miR-205-5p, miR-203-3p and miR-
182-5p (Figure 2). No clear distinctive clusters of melanoma
cases in relation to metastatic status emerged. 
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By comparing miRNA expression levels among primary
non-metastatic melanomas, primary metastatic melanomas
and metastases, statistically significant differences emerged
in the expression levels of miR-145-5p, miR-203-3p and
miR-205-5p (Figure 3). In particular, miR-145-5p and miR-
203-3p showed decreased expression levels in metastases
compared with primary non-metastatic tumors (p=0.05 and
p=0.02, respectively), whereas miR-205-5p showed
significantly lower expression levels in metastases compared
with primary metastatic melanomas (p=0.04). 
MiR-205-5p expression was further compared in the three
cases of primary metastatic melanoma and their
corresponding metastasis (Figure 4a). The difference in miR-
205-5p expression between primary tumor and
corresponding metastasis varied in relation to the site of
metastasis. In particular, miR-205-5p expression was 6- and
54-fold higher in the primary melanomas compared with the
relative lymph node and lung metastasis, respectively. MiR-
205-5p expression was also examined in all eight metastatic
specimens according to the metastatic site (Figure 4b).
Overall, a progressive down-regulation of miR-205-5p
expression was observed from loco-regional metastasis
(cutaneous and lymph node metastasis) to distant metastasis
(lung metastasis). 
Possible differences in miRNAs expression levels among
primary tumors were also investigated considering thin and
thick melanomas separately. No statistically significant
differences in the expression levels of the six miRNAs
analyzed emerged. However, the expression levels of miR-
145-5p, miR-150-5p and miR-205-5p showed an opposite
trend in non-metastatic and metastatic cases when comparing
thin and thick melanomas (Figure 5). Furthermore, when
considering median expression levels in thin and thick
melanomas in relation to metastatic status, higher median
Valentini et al: miRNAs Expression Profile in Cutaneous Melanomas
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Table I. Clinical-pathological characteristics of the 32 primary
cutaneous melanoma cases analyzed in this study. 
Clinical-pathological characteristics                                 N (%)
Mean age at diagnosis±SD (range)                        59.3±20.1 (18-92)
Gender                                                                                     
   Male                                                                           17 (53.1%)
   Female                                                                        15 (46.9%)
Breslow thickness                                                                   
   ≤1 mm (thin)                                                              16 (50.0%)
   >1 mm (thick)                                                            16 (50.0%)
Clark level                                                                               
   II                                                                                   2 (6.2%)
   III                                                                                15 (46.9%)
   IV                                                                                 9 (28.1%)
   V                                                                                  6 (18.7%)
Ulceration                                                                               
   Absent                                                                        26 (81.2%)
   Present                                                                         6 (18.7%)
TIL grade                                                                                
   0                                                                                   6 (18.7%)
   I                                                                                   11 (34.4%)
   II                                                                                 12 (37.5%)
   III                                                                                  3 (9.4%)
Mitotic rate (N/mm2)                                                             
   <1/mm2                                                                       17 (53.1%)
   ≥1/mm2                                                                       15 (46.9%)
N: Number of cases; SD: standard deviation; TIL: Tumor-infiltrating
lymphocyte; (N/mm2): number of mitoses/mm2.
Figure 1. Diagram showing the distribution of 32 primary cutaneous melanoma cases analyzed in this study. Thin and Thick refers to melanomas
with Breslow thickness ≤1 mm and >1 mm, respectively.
expression levels of miR-145-5p, miR-182-5p, miR-203-3p
and miR-205-5p were observed in metastatic thin melanomas
compared with non-metastatic thick melanomas. In
particular, for miR-203-3p, a progressive decrease in
expression levels was observed from thin non-metastatic to
thick metastatic melanomas. 
Association between miRNA expression and clinical-
pathological characteristics of primary melanomas. For each
miRNA, association between expression levels and clinical-
pathological characteristics of the 32 primary melanoma
cases was evaluated (Table II). Overall, a significant
association between lower expression of miR-145-5p and
miR-203-3p and pathological characteristics indicative of
aggressiveness was observed. In particular, significantly
lower miR-145-5p and miR-203-3p expression levels were
found in cases with Breslow thickness >1 mm (p=0.002 and
p=0.005, respectively), high Clark level (p=0.007 and
p=0.005, respectively), ulceration (p=0.00001 and
p=0.0002, respectively) and mitotic rate ≥1/mm2 (p=0.02
and p=0.001 respectively). Significantly lower miR-182-5p
expression levels were also observed in cases with Breslow
thickness >1 mm (p=0.03) and high Clark level (p=0.03). 
Discussion
In this study, we explored the possible role of miRNAs,
known to be involved in the metastatic process, as prognostic
biomarkers for metastasis in melanoma. To this aim, the
expression profile of mature miRNAs for miR-145-5p, miR-
150-5p, miR-182-5p, miR-203-3p, miR-205-5p and miR-
211-5p was investigated in primary non-metastatic
melanomas, primary metastatic thin and thick melanomas
and in metastases.
In line with previously reported findings, our study
showed lower expression levels of miR-145-5p, miR-203-3p
and miR-205-5p in metastases compared to primary tumors,
highlighting their role in metastasis (16, 25-29). 
In particular, our results indicate significantly lower miR-
205-5p expression in metastases compared with primary
metastatic melanomas. Comparing the expression of miR-
205-5p between primary metastatic melanomas and their
corresponding metastases, the ratio (primary/metastasis) was
found to higher with increasing metastases distance. In fact,
the evaluation of miR-205-5p in metastases according to
their location, showed a progressive decrease in expression
from loco-regional (cutaneous and lymph node) to distant
(lung) metastases, thus suggesting that the down-regulation
of miR-205-5p expression might promote the development
of distant metastases. These results are consistent with recent
findings showing a progressive loss of miR-205-5p along the
full spectrum of melanoma progression, from primary tumor
to distant metastasis (19).  
Several studies suggest that miR-205-5p is a tumor
suppressor miRNA in melanoma and has a role in the
regulation of melanoma cell invasiveness (19, 30), mainly
through the regulation of zinc-finger E-box binding
homeobox 2 (ZEB2) and E-cadherin expression (31).
However, although the role of miR-205-5p as tumor
suppressor in melanoma is well established, its use as
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Figure 2. Unsupervised hierarchical clustering analysis of relative expression levels of target miRNAs in 32 samples (including 14 primary non-
metastatic melanomas, 12 primary metastatic melanomas and 6 metastases), for which data on expression levels of all miRNAs examined were
available. 
molecular biomarker has not yet been validated. Overall, our
findings add evidence supporting the utility of miR-205-5p
as a prognostic marker in melanoma, particularly for the
selection of patients at risk of developing distant metastases. 
In our study, lower miR-145-5p and miR-203-3p expression
levels in primary melanomas were significantly correlated
with pathological characteristics suggestive of aggressiveness,
including Breslow thickness >1 mm, high Clark level,
Valentini et al: miRNAs Expression Profile in Cutaneous Melanomas
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Figure 3. Comparison of relative expression levels of miR-145-5p (a), miR-150-5p (b), miR-182-5p (c), miR-203-3p (d), miR-205-5p (e) and miR-
211-5p (f) in samples of primary non-metastatic melanomas, metastatic melanomas and metastases.  Results of miRNA expression analysis are
shown as log values in boxplots. Statistically significant p-values are reported.
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Figure 4. Relative expression levels of miR-205-5p in the three primary metastatic tumors and their corresponding metastasis (a) and in all the
metastatic specimens available (N=8), stratified according to metastatic site (b). *miR-205-5p expression ratio calculated as primary tumor versus
corresponding metastasis.
Table II. Associations between relative miRNA expression levels and clinical-pathological characteristics in the 32 primary cutaneous melanoma
cases analyzed in this study.
                                                miR-145-5p                  miR-150-5p                 miR-182-5p             miR-203-3p              miR-205-5p           miR-211-5p
                                                    Median                         Median                        Median                     Median                     Median                   Median
Gender                                                                                                                                                                                                                  
   Male                                          2.98                                6.31                              1.40                          5.78                         16.20                      2.10
   Female                                        3.73                                4.10                              1.65                          5.50                         15.80                      2.70
   p-value                                       0.82                                0.35                              0.82                          0.31                           0.31                      0.33
Breslow thickness                                                                                                                                                                                                
   ≤1 mm (thin)                             4.24                                6.06                              1.64                          7.03                         16.44                      1.96
   >1 mm (thick)                            1.41                                3.18                              0.81                          3.55                         12.71                      3.67
   p-value                                       0.002                              0.51                              0.03                          0.005                         0.30                      0.17
Clark level                                                                                                                                                                                                           
   II                                                 3.85                                1.70                              9.31                        12.70                         34.1                        1.49
   III                                               4.56                                6.08                              1.60                          6.52                         15.8                        2.04
   IV                                               1.39                                1.66                              0.61                          2.36                           8.20                      4.46
   V                                                 1.17                                7.01                              1.22                          4.40                         37.63                      1.62
   p-value                                       0.007                              0.12                              0.03                          0.005                         0.06                      0.39
Ulceration                                                                                                                                                                                                            
   Absent                                       3.62                                5.76                              1.55                          6.45                         16.44                      2.51
   Present                                        0.80                                4.04                              0.61                          1.60                           9.01                      1.52
   p-value                                       0.00001                          0.55                              0.13                          0.0002                       0.07                      0.45
TIL grade                                                                                                                                                                                                             
   0                                                  3.89                                4.79                              1.23                          3.50                         13.60                      2.04
   I                                                  2.11                                2.57                              1.47                          6.66                         16.20                      2.45
   II                                                 3.53                                6.93                              1.26                          5.01                         15.02                      2.20
   III                                               3.73                                8.88                              2.11                          6.52                         19.90                      2.93
   p-value                                       0.78                                0.07                              0.36                          0.33                           0.89                      0.94
Mitotic rate (N/mm2)                                                                                                                                                                                          
   <1/mm2                                      3.89                                6.31                              1.60                          6.79                         16.20                      2.45
   ≥1/mm2                                      1.43                                5.41                              0.81                          2.68                         11.36                      2.16
   p-value                                       0.02                                0.31                              0.06                          0.001                         0.45                      0.86
Bold p-values are considered statistically significant. TIL: Tumor-infiltrating lymphocyte; (N/mm2): number of mitoses/mm2.
ulceration and mitotic rate ≥1/mm2. MiR-145-5p and miR-
203-3p play a key role as tumor suppressor miRNAs and both
miRNAs were down-regulated in melanoma (20). MiR-145-
5p inhibits the invasive and metastatic capacity of neoplastic
cells by repressing fascin homolog 1 (FSCN1) (21, 25) and
the ectopic expression of miR-145-5p in melanoma cell lines,
resulting in a decrease in cell growth and invasiveness through
targeting c- MYC (29). By repressing different target genes, a
similar suppressive effect was observed for miR-203-3p (27,
28). In particular, miR-203-3p inhibited the proliferation
through targeting B lymphoma Mo-MLV insertion region 1
homolog (BMI1) (32) and the ectopic expression of miR- 203-
3p in melanoma cells reduced the expression of E2F3a and
E2F3b, leading to the inhibition of cell growth (29). Taking
into account these observations, our findings suggest that in
primary melanomas, miR-145-5p and miR-203-3p may be
Valentini et al: miRNAs Expression Profile in Cutaneous Melanomas
4091
Figure 5. Comparison of relative expression levels of miR-145-5p (a), miR-150-5p (b), miR-182-5p (c), miR-203-3p (d), miR-205-5p (e) and miR-
211-5p (f) in primary thin and thick melanomas stratified according to metastatic behavior. Results of miRNA expression analysis are shown as log
values in boxplots.
involved in the regulation of tumor growth and invasion.
Further studies are needed in order to support the clinical
relevance of miR145-5p and miR-203-3p expression as
prognostic biomarkers for metastatic melanomas. 
We also showed that the stratification of miR-145-5p
expression according to Breslow thickness and metastatic
behavior highlighted an opposite trend in the expression levels
of this miRNA between non-metastatic and metastatic cases
in thin compared to thick melanomas. This tendency was also
observed for miR-150-5p and miR-205-5p. These results
suggest a molecular heterogeneity in the metastatic process in
relation to thickness and may indicate that different molecular
mechanisms could mediate disease progression and metastasis
development in thin compared to thick melanomas. To date,
only few studies have investigated the molecular processes
underlying thin melanoma pathogenesis and no molecular
predictor of disease progression has been identified (30, 33-
35). Overall, our results add evidence supporting the
hypothesis that thin melanoma cannot be considered just an
early stage of melanoma progression but, at least in some
cases, a different type of tumor (33). 
In conclusion, our findings add insights into the
characterization of miRNAs expression profile of thin and
thick melanomas, pointing to miR-205-5p as a potential
biomarker of distant metastases and to miR-145-5p and miR-
203-3p as biomarkers of aggressiveness in primary tumors. 
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